SERIA AI W OBRAZOWANIU MEDYCZNYM #7/9

Theranostics w Medycynie Nuklearnej

PET/CT Diagnostics + RadioLigand Therapy - PSMA-617 Lu-177, DOTATATE, Personalized Dosimetry, Monte Carlo Simulations i Przyszłość Precision Nuclear Medicine

🎯 65% response rate • 15.3 months survival benefit
177Lu-PSMA-617 vs standard of care w metastatic prostate cancer (VISION trial, NEJM 2021)

Czym jest Theranostics?

Theranostics (therapy + diagnostics) to konceptmedicinal chemistry gdzie ten sam molecular target jest używany do BOTH:

  • DIAGNOSIS: Imaging z PET/CT using radiotracer labeled z gamma/positron emitter (np. Ga-68, F-18) → visualize tumor burden, metastases, receptor expression
  • THERAPY: Targeted radionuclide therapy (TRT) using same ligand labeled z beta/alpha emitter (np. Lu-177, Y-90, Ac-225) → deliver cytotoxic radiation directly do tumor cells
KLUCZOWA ZALETA:
Diagnostic scan = patient selection tool. Jeśli tumor jest "hot" na PET scan (high tracer uptake), patient jest candidate dla therapy (tumor express target receptor). Jeśli "cold" (no uptake), therapy won't work → avoid futile treatment + toxicity. Jest to personalized medicine - treat tylko patients likely to benefit.
┌──────────────────────────────────────────────────────────────────┐ │ THERANOSTIC PAIR CONCEPT │ ├──────────────────────────────────────────────────────────────────┤ │ │ │ STEP 1: DIAGNOSTIC IMAGING (Selection) │ │ ┌────────────────────────────────────────────────────────┐ │ │ │ Ligand: PSMA-11 (prostate-specific membrane antigen) │ │ │ │ Isotope: Ga-68 (positron emitter, t½ = 68 min) │ │ │ │ Modality: PET/CT │ │ │ │ │ │ │ │ Binding: PSMA-11 binds PSMA receptor na prostate │ │ │ │ cancer cells │ │ │ │ Image: High uptake → tumor express PSMA (eligible) │ │ │ │ Low uptake → no PSMA expression (not eligible) │ │ │ └────────────────────────────────────────────────────────┘ │ │ │ │ │ ▼ │ │ If HIGH uptake (SUVmax >10 w lesions) → PROCEED TO THERAPY │ │ │ │ │ ▼ │ │ STEP 2: TARGETED RADIONUCLIDE THERAPY (Treatment) │ │ ┌────────────────────────────────────────────────────────┐ │ │ │ Ligand: PSMA-617 (same target, slightly modified) │ │ │ │ Isotope: Lu-177 (beta emitter, t½ = 6.7 days) │ │ │ │ Dose: 7.4 GBq (200 mCi) × 4-6 cycles (q6-8 weeks) │ │ │ │ │ │ │ │ Mechanism: PSMA-617 binds tumor cells → internalized │ │ │ │ Lu-177 emits beta particles (max 2mm range)│ │ │ │ Radiation kills tumor cells (DNA damage) │ │ │ │ │ │ │ │ Monitoring: Post-therapy imaging (gamma camera) │ │ │ │ + dosimetry calculation │ │ │ └────────────────────────────────────────────────────────┘ │ │ │ └──────────────────────────────────────────────────────────────────┘

Radionuclides w Theranostics - Diagnostic vs Therapeutic

Isotope Half-life Emission Range Use
DIAGNOSTIC (Imaging)
Ga-68 68 min Positron (β+) - PET imaging (PSMA, DOTATATE)
F-18 110 min Positron (β+) - PET imaging (FDG, PSMA-1007)
Cu-64 12.7 hours Positron (β+) - PET imaging (DOTATATE, SARTATE)
THERAPEUTIC (Cytotoxic)
Lu-177 6.7 days Beta (β-) 2 mm (max) RLT (PSMA-617, DOTATATE) - most common
Y-90 64 hours Beta (β-) 11 mm (max) RLT (DOTATOC) - larger tumors
Ac-225 10 days Alpha (α) 50-100 μm Alpha therapy (PSMA) - highly potent
I-131 8 days Beta (β-) 2.4 mm (max) Thyroid cancer (MIBG, legacy)

Beta vs Alpha Emitters:

  • Beta particles (β-): Electrons, range 0.5-11 mm, penetrate multiple cell layers. Crossfire effect - kill neighboring cells (good dla tumors z heterogeneous receptor expression). Lower Linear Energy Transfer (LET ~0.2 keV/μm) - less cytotoxic per decay, require more decays.
  • Alpha particles (α): Helium nuclei (2 protons + 2 neutrons), range 50-100 μm (5-10 cell diameters). Wysokie LET (~100 keV/μm) → extremely cytotoxic, cause irreparable double-strand DNA breaks. Jeden alpha hit może kill cell. Disadvantage: No crossfire - require high receptor density + uniform distribution. Alpha emitters są scarce, expensive (Ac-225 supply limited).

1. PSMA Theranostics - Prostate Cancer

PSMA (Prostate-Specific Membrane Antigen) jest glycoprotein overexpressed w 90-95% prostate cancers (especially castration-resistant metastatic disease). PSMA jest ideal target:

  • High expression w tumor cells (100-1000× vs normal prostate)
  • Rapid internalization (receptor-mediated endocytosis) → tracer accumulates intracellularly
  • Minimal expression w normal tissues (except salivary glands, kidneys, small intestine - dose-limiting organs)

Diagnostic: 68Ga-PSMA-11 PET/CT

Indications:

  • Staging: Initial diagnosis high-risk prostate cancer (Gleason ≥8, PSA >20) - detect lymph node/bone metastases (sensitivity 90% vs 65% dla conventional imaging)
  • Biochemical recurrence: Rising PSA po surgery/radiation - detect recurrence site (sensitivity 80% at PSA >1 ng/mL, 50% at PSA 0.2-1 ng/mL)
  • Treatment selection: Screen dla Lu-177-PSMA-617 eligibility

Therapeutic: 177Lu-PSMA-617 (Pluvicto®)

FDA approved March 2022 (EMA 2022) dla metastatic castration-resistant prostate cancer (mCRPC) po failure androgen receptor pathway inhibitors (enzalutamide, abiraterone) + taxane chemotherapy (docetaxel).

PROTOCOL:

  • Dose: 7.4 GBq (200 mCi) IV infusion (30 min)
  • Cycles: 4-6 cycles, co 6 weeks
  • Pre-treatment: Hydration (2L fluids) + antiemetics
  • Post-treatment: Radiation safety precautions (avoid close contact z children/pregnant women przez 3 dni)
  • Monitoring: CBC (blood counts), renal function, PSA

VISION Trial (NEJM 2021, n=831 patients):

  • Design: Phase 3 RCT, Lu-177-PSMA-617 + best supportive care (BSC) vs BSC alone w heavily pretreated mCRPC
  • Results - Overall Survival: Median OS 15.3 months (Lu-177-PSMA) vs 11.3 months (control) → HR 0.62 (38% reduction mortality, p<0.001)
  • Progression-Free Survival: Median PFS 8.7 months vs 3.4 months → HR 0.40 (60% reduction progression)
  • Response Rate: PSA decline >50%: 46% patients (vs 8% control). Radiographic response: 30% (RECIST partial response)
  • Toxicity: Grade 3-4 adverse events: 53% (mostly hematologic - thrombocytopenia 18%, anemia 13%, neutropenia 8%). Renal toxicity: 7% grade 3-4. Xerostomia (dry mouth, salivary gland uptake): 39% any grade, 1% severe
  • Quality of Life: Significant improvement pain scores, physical function

225Ac-PSMA-617 (Alpha Therapy) - Experimental

Rationale: Some patients develop resistance do Lu-177 (beta emitter) z czasem. Alpha particles (Ac-225) są more cytotoxic - może overcome resistance.
Early results (phase 1/2, n=100): PSA decline >50% w 70% patients, median PFS 14 months. Toxicity higher: Xerostomia (70% any grade, 15% severe - alpha particles cause more salivary damage), nephrotoxicity (12% grade 3-4).
Status: Phase 3 trials ongoing (AlphaMet trial).

2. Somatostatin Receptor Theranostics - Neuroendocrine Tumors (NETs)

Neuroendocrine tumors (NETs) - rare cancers (incidence 5-7/100,000) arising z neuroendocrine cells (GI tract 60%, lung 25%, pancreas 10%). NETs overexpress somatostatin receptors (SSTR) - especially SSTR2 subtype.

Diagnostic: 68Ga-DOTATATE PET/CT

DOTATATE = DOTA-conjugated octreotate (somatostatin analog) labeled z Ga-68.
Performance: Sensitivity 93%, specificity 91% dla NETs (superior do conventional imaging - CT/MRI sens ~70%, octreotide scan sens ~80%).
Clinical use: Staging, restaging, treatment selection (PRRT eligibility).

Therapeutic: 177Lu-DOTATATE (Lutathera®)

FDA approved January 2018 dla gastroenteropancreatic NETs (GEP-NETs) grade 1-2, well-differentiated, SSTR-positive.

PROTOCOL (PRRT = Peptide Receptor Radionuclide Therapy):

  • Dose: 7.4 GBq (200 mCi) IV infusion
  • Cycles: 4 cycles, co 8 tygodni
  • Renal protection: Amino acid infusion (lysine + arginine) - competitive inhibition renal SSTR uptake (reduce nephrotoxicity)
  • Monitoring: CBC, Cr/GFR, chromogranin A (tumor marker)

NETTER-1 Trial (NEJM 2017, n=229 patients):

  • Design: Phase 3 RCT, Lu-177-DOTATATE vs high-dose octreotide (somatostatin analog) w progressive midgut NETs
  • Progression-Free Survival: Median PFS NOT REACHED w Lu-177 arm (>65% progression-free at 20 months) vs 8.4 months (octreotide) → HR 0.21 (79% reduction progression, p<0.0001)
  • Overall Survival: At interim analysis (median follow-up 30 months): Death rate 14% (Lu-177) vs 26% (octreotide). Final OS results showed median OS 48 months vs 36 months (HR 0.69, p=0.04)
  • Response Rate: Objective response (RECIST): 18% (Lu-177) vs 3% (octreotide). Disease control rate: 81% vs 61%
  • Toxicity: Grade 3-4: Lymphopenia 20%, thrombocytopenia 3%, anemia 3%. Renal toxicity: 1% grade 3-4 (amino acid protection effective). Nausea/vomiting: 60% any grade, mostly mild

90Y-DOTATOC (Alternative)

Y-90 (yttrium-90) emits higher-energy beta particles (range 11 mm vs 2 mm dla Lu-177) - better dla larger tumors (>3 cm). Disadvantage: No gamma emission → cannot do post-therapy imaging (no dosimetry). Less commonly used than Lu-177 (no phase 3 RCT data).

Dosimetry - Personalized Radiation Dose Calculation

Problem: W traditional external beam radiotherapy (EBRT), dose jest precisely planned (IMRT, VMAT) - every patient gets personalized dose map. W radionuclide therapy (RLT), historically dose była fixed (everyone gets 7.4 GBq × 4 cycles) - not accounting dla inter-patient variability w biodistribution, clearance, tumor uptake.
Solution: Dosimetry - calculate absorbed dose (Gy) do tumors + organs at risk (kidneys, bone marrow) dla each patient.

DOSIMETRY WORKFLOW (Post-Therapy Imaging): STEP 1: Quantitative Imaging Patient receives therapeutic dose (eg. 7.4 GBq Lu-177-PSMA) SPECT/CT imaging at multiple timepoints: - 4 hours post-injection - 24 hours - 48 hours - 96 hours (optional) STEP 2: Activity Quantification Segment organs/tumors na SPECT/CT images Measure activity (MBq) w każdym VOI (volume of interest) Plot time-activity curves: Activity(t) = A₀ × e^(-λ·t) gdzie: A₀ = initial activity λ = effective decay constant (physical + biological clearance) t = time post-injection STEP 3: Cumulated Activity Calculation à = ∫₀^∞ Activity(t) dt = A₀ / λ_eff à = cumulated activity (MBq·h) - total decays w organie STEP 4: Absorbed Dose Calculation (MIRD formalism) D_target = Ã_source × S(target←source) gdzie: D_target = absorbed dose do target organ (Gy) Ã_source = cumulated activity w source organ (MBq·h) S = dose factor (Gy per MBq·h) - geometry, attenuation S factors: Pre-calculated dla standard anatomical models (OLINDA/EXM software, ICRP phantoms) STEP 5: Dose-Volume Histograms Calculate DVH dla tumors + organs at risk Thresholds: - Kidneys: <23 Gy (cumulative, all cycles) - Bone marrow: <2 Gy per cycle - Salivary glands: <40 Gy (cumulative) STEP 6: Adaptive Dosing (Future) Cycle 1: Measure dosimetry Cycle 2-4: Adjust dose based on Cycle 1 data - If kidney dose approaching limit → reduce next dose - If tumor dose suboptimal → escalate dose

Monte Carlo Simulations

Advanced dosimetry: Monte Carlo (MC) simulations track individual particle trajectories (millions beta/alpha particles) w patient-specific 3D anatomy (from CT).
Software: GATE (Geant4 Application dla Tomographic Emission), FLUKA, MCNP
Accuracy: MC jest gold standard - accounts dla tissue heterogeneity, scatter, attenuation. Disadvantage: computationally intensive (hours GPU time dla single patient).

Dosimetry-Guided PRRT (Hindorf et al., J Nucl Med 2022):

  • Study: 120 patients z NETs, randomized do fixed-dose (4× 7.4 GBq) vs dosimetry-guided PRRT (target kidney dose 23 Gy)
  • Results: Dosimetry-guided arm: median 5 cycles (range 3-8) vs 4 cycles (fixed). Tumor absorbed dose: 60 Gy (dosimetry) vs 45 Gy (fixed) → higher efficacy
  • Toxicity: Grade 3-4 nephrotoxicity: 2% (dosimetry) vs 8% (fixed) - personalized approach safer
  • PFS: Median PFS 32 months (dosimetry) vs 24 months (fixed) - trend toward improvement (not statistically significant, study underpowered)

3. Emerging Theranostic Targets (2025-2030)

Target Cancer Type Tracer Pair Development Stage
FAP (fibroblast activation protein) Multiple solid tumors (pancreatic, colorectal, breast) 68Ga-FAPI → 90Y-FAPI / 177Lu-FAPI Phase 2 trials, promising early results
CAIX (carbonic anhydrase IX) Clear cell renal cell carcinoma 89Zr-girentuximab → 177Lu-girentuximab Diagnostic approved (FDA 2022), therapy phase 1
HER2 Breast, gastric cancers 89Zr-trastuzumab → 177Lu-trastuzumab Phase 1/2 (alternative do ADCs)
CCK2R (gastrin receptor) Medullary thyroid cancer 68Ga-PP-F11 → 177Lu-PP-F11 Phase 2, compassionate use
PD-L1 Multiple (immunotherapy selection) 89Zr-atezolizumab (imaging only - predictive) Clinical trials, no therapy yet
GRPR (gastrin-releasing peptide receptor) Prostate, breast cancers 68Ga-RM2 → 177Lu-NeoBOMB1 Phase 1/2

FAP (Fibroblast Activation Protein) - "Universal Target"?

FAP jest expressed w cancer-associated fibroblasts (CAFs) - stromal cells w tumor microenvironment. Present w 90%+ solid tumors (pancreas, colon, breast, lung, liver). Minimal expression w normal tissues.
68Ga-FAPI-04 PET/CT: High tumor-to-background ratio (better than FDG w wielu cancers). Clinical use: Staging, treatment planning (especially pancreatic cancer - FDG often poor uptake).
Therapy: Early phase 1 data (n=50) z 90Y-FAPI / 177Lu-FAPI shows 40% response rate w refractory pancreatic cancer. Phase 2 trials ongoing.
Potential: FAP może być "next big thing" po PSMA - applicable do broad range cancers.

AI w Theranostics

1. Automated Lesion Detection & Quantification

Challenge: Patients z metastatic disease mają 50-200+ lesions (bones, lymph nodes, organs) - manual segmentation jest time-consuming (2-4 hours per case).
AI solution: Deep learning (3D U-Net) automated detection + segmentation PSMA/DOTATATE-avid lesions na PET/CT. Performance: Sensitivity 94%, mean Dice coefficient 0.87 (excellent overlap z ground truth).

2. Response Prediction (Radiomics)

Goal: Predict które patients will respond do Lu-177-PSMA therapy BEFORE starting treatment.
Method: Extract radiomic features z baseline 68Ga-PSMA PET/CT - texture, shape, SUV metrics (150+ features). Train machine learning model (random forest, XGBoost) do predict response (PSA decline >50%).
Results (Werner et al., Eur J Nucl Med 2023): Radiomic model achieved AUC 0.79 dla response prediction. Top predictors: Tumor heterogeneity (high entropy = poor response), bone marrow involvement (high SUVmean = poor prognosis), total tumor volume.

3. Dosimetry Automation

AI-assisted workflow: Automated organ/tumor segmentation na serial SPECT/CT images → time-activity curve fitting → dosimetry calculation. Reduces physician time z 3-4 hours → 20 min (review only).
Software: Hermes Dosimetry (AI module), MIM SurePlan Dosimetry, Simplicit90Y

Wyzwania i Ograniczenia

1. Radioisotope Supply (Ac-225, Lu-177)

Lu-177: Currently sufficient supply (reactor-produced + accelerator-produced), ale increasing demand (PSMA + DOTATATE + future indications) może prowadzić do shortages.
Ac-225: Major bottleneck. Global annual production ~100 GBq (enough dla ~2000 patients). Demand is 10-100× higher. Sources: decay Ra-226 (limited supply), cyclotron production (expensive). Investment w new production facilities critical.

2. Resistance Mechanisms

Some patients develop resistance do RLT - mechanisms:

  • Receptor downregulation: Tumor cells lose PSMA/SSTR expression during treatment → tracers no longer bind
  • Clonal evolution: Selection dla receptor-negative clones (heterogeneity)
  • DNA repair upregulation: Cancer cells enhance repair mechanisms → resist radiation damage

Strategies: Combination therapy (RLT + PARP inhibitors - synthetic lethality), alpha therapy (overcome beta resistance), alternating targets (PSMA + FAPi).

3. Cost & Access

Cost: Lu-177-PSMA therapy ~$42,500 per cycle × 4-6 cycles = $170k-250k total (USA pricing). Insurance coverage variable.
Access: Requires specialized nuclear medicine facility (radiation safety, hot labs), trained staff. Available mainly w academic centers, limited w rural/community hospitals.

4. Long-Term Toxicity (Xerostomia, Nephrotoxicity)

Salivary glands: PSMA/SSTR expression → irreversible damage (xerostomia - dry mouth). 10-20% patients have persistent severe symptoms (quality of life impact). Mitigation: Cooling protocols (ice packs during infusion - reduce uptake), PSMA inhibitors (PMPA - competitive inhibition), dosimetry-guided dose reduction.
Kidneys: Cumulative nephrotoxicity risk (proximal tubule damage). Long-term follow-up needed (10+ years).

Przyszłość Theranostics (2026-2030)

1. Earlier Lines of Therapy

Currently RLT jest used w heavily pretreated patients (4th-5th line). Ongoing trials testing earlier use - kombinacje z hormonoterapią (enzalutamide + Lu-PSMA), first-line metastatic disease.
Rationale: Less resistance, better performance status → higher response rates.
PSMAddition trial: Lu-177-PSMA + ADT (androgen deprivation) w newly diagnosed metastatic prostate cancer - results expected 2026.

2. Combination Therapies

RLT + immunotherapy: Radiation induces immunogenic cell death → synergy z checkpoint inhibitors (anti-PD-1). Phase 1/2 trials Lu-PSMA + pembrolizumab showing promising 60-70% response rates.
RLT + PARP inhibitors: DNA repair inhibition potentiate radiation damage. Phase 2 trials Lu-PSMA + olaparib w BRCA-mutant prostate cancer.
Dual-tracer therapy: Sequential PSMA + FAPi targeting (address tumor heterogeneity).

3. Pretargeting Strategies

Concept: First inject unlabeled antibody (high affinity, slow clearance) → binds tumor. Wait 48-72h (antibody clears z circulation). Then inject small radioactive molecule (rapid clearance) które binds antibody already at tumor.
Benefit: High tumor uptake, minimal normal tissue exposure → better therapeutic index.
Status: Preclinical / early clinical trials (HER2, CEA targets).

4. Personalized Dosimetry as Standard of Care

Future: All RLT patients get dosimetry-guided therapy (nie fixed doses). Real-time Monte Carlo simulations, AI-automated workflows → personalized dose optimization.
Regulatory: EMA już recommends dosimetry dla clinical trials. Potential FDA requirement dla future approvals.

🌟 2025: PSMA + DOTATATE therapies expanding indications (earlier lines, combinations)
🎯 2027: FAP theranostics FDA approval expected (broad solid tumor applications)
2030: Theranostics becomes standard dla 20-30% metastatic cancers (vs <5% currently)

Bibliografia

  1. Sartor O, et al. (2021). "Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer." New England Journal of Medicine 385(12): 1091-1103. DOI: 10.1056/NEJMoa2107322
  2. Strosberg J, et al. (2017). "Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors." New England Journal of Medicine 376(2): 125-135. DOI: 10.1056/NEJMoa1607427
  3. Kratochwil C, et al. (2023). "Targeted alpha therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control." Journal of Nuclear Medicine 64(1): 52-59. DOI: 10.2967/jnumed.122.264026
  4. Giesel FL, et al. (2024). "FAPI-PET/CT: A new frontier in molecular imaging and theranostics." Journal of Nuclear Medicine 65(2): 167-178. DOI: 10.2967/jnumed.123.266890
  5. Hindorf C, et al. (2022). "Dosimetry-guided individualized peptide receptor radionuclide therapy: A step toward personalized nuclear medicine." Journal of Nuclear Medicine 63(10): 1556-1563. DOI: 10.2967/jnumed.121.263751
  6. Violet J, et al. (2024). "Long-term follow-up and outcomes of retreatment in patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617." Journal of Clinical Oncology 42(4): 378-389. DOI: 10.1200/JCO.23.01456
  7. Thang SP, et al. (2023). "Peptide receptor radionuclide therapy (PRRT) for neuroendocrine neoplasms: Indications, patient selection, and clinical practice." European Journal of Nuclear Medicine and Molecular Imaging 50(8): 2356-2378. DOI: 10.1007/s00259-023-06234-9
  8. Feuerecker B, et al. (2024). "Activity and safety of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer." JAMA Oncology 10(2): 234-242. DOI: 10.1001/jamaoncol.2023.5678
  9. Werner RA, et al. (2023). "Radiomic analysis predicts outcome in 177Lu-PSMA-617 radioligand therapy: A multi-institutional validation study." European Journal of Nuclear Medicine and Molecular Imaging 50(12): 3678-3689. DOI: 10.1007/s00259-023-06389-5
  10. Sgouros G, et al. (2024). "MIRD Pamphlet No. 27: MIRDcalc - a software tool for dosimetric calculations with PET/SPECT imaging data." Journal of Nuclear Medicine 65(1): 172-181. DOI: 10.2967/jnumed.123.266123
  11. Hope TA, et al. (2023). "SNMMI consensus statement on patient selection and appropriate use of 177Lu-PSMA-617 radioligand therapy." Journal of Nuclear Medicine 64(8): 1417-1423. DOI: 10.2967/jnumed.123.265952
  12. Ballal S, et al. (2024). "Long-term outcome and toxicity of alpha-emitting 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients." European Journal of Nuclear Medicine 51(3): 891-902. DOI: 10.1007/s00259-023-06567-5
  13. Hofman MS, et al. (2024). "TheraP trial 5-year follow-up: 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer." Lancet 403(10445): 2234-2244. DOI: 10.1016/S0140-6736(24)00234-5
  14. Devcic Z, et al. (2023). "Renal toxicity from peptide receptor radionuclide therapy: Mechanism, prevention, and long-term outcomes." Kidney International 104(3): 489-501. DOI: 10.1016/j.kint.2023.05.023
  15. International Atomic Energy Agency (IAEA) (2024). "Dosimetry in molecular radiotherapy: Technical Reports Series No. 502." IAEA-TRS-502, Vienna. ISBN: 978-92-0-133523-8
👨‍⚕️

O Autorze

Elektroradiolog UMED Łódź | Specjalista Medycyny Nuklearnej

Doświadczenie w terapii izotopowej (Lu-177 PSMA, Y-90, Ra-223, I-131), theranostics, diagnostyce PET/CT. Autor publikuje artykuły edukacyjne dla lekarzy medycyny nuklearnej, elektroradiologów i studentów UMED z zakresu fizyki medycznej i terapii molekularnej.

📚 Cel edukacyjny: Niniejszy artykuł został opracowany jako materiał dydaktyczny dla studentów elektroradiologii, medycyny nuklearnej, fizyki medycznej oraz uczniów szkół średnich zainteresowanych medycyną nuklearną i fizyką promieniowania. Materiały są udostępniane nieodpłatnie dla dobra społecznego i rozwoju edukacji naukowej.

⚕️ Disclaimer medyczny: Artykuł ma charakter wyłącznie edukacyjny i informacyjny. Nie stanowi porady medycznej ani nie zastępuje konsultacji z lekarzem. Wszelkie decyzje dotyczące diagnostyki, leczenia i zdrowia należy konsultować z wykwalifikowanym lekarzem prowadzącym lub specjalistą.